AYTU BIOPHARMA, INC. (AYTU) Return on equity 2017–2026
AYTU BIOPHARMA, INC. (AYTU) return on equity by fiscal year — reported net income divided by year-end shareholders’ equity.
-40.4%FY2026 · since FY2017: -562.7% → -40.4%
| Fiscal year | Value | YoY |
|---|---|---|
| FY2026 | -40.4% | +31.1 pp |
| FY2025 | -71.5% | -14.3 pp |
| FY2024 | -57.2% | -13.8 pp |
| FY2023 | -43.3% | +202.2 pp |
| FY2022 | -245.5% | -203.1 pp |
| FY2021 | -42.4% | -28.0 pp |
| FY2020 | -14.3% | +368.5 pp |
| FY2019 | -382.8% | -306.9 pp |
| FY2018 | -75.9% | +486.8 pp |
| FY2017 | -562.7% | — |
ROE = reported net income ÷ reported year-end shareholders’ equity for the same fiscal year. Heavy buybacks shrink equity and can push ROE very high (or negative-equity years drop out).
Source: SEC XBRL filings · For reference only · Not investment advice
More AYTU financial trends
AYTU RevenueAYTU Net incomeAYTU Net marginAYTU Gross profitAYTU Gross marginAYTU Operating incomeAYTU Operating marginAYTU Operating cash flowAYTU Free cash flowAYTU Capital expendituresAYTU Stock buybacksAYTU Dividends paidAYTU Total assetsAYTU Total liabilitiesAYTU Shareholders’ equityAYTU overview →